NFKB1 and rheumatoid arthritis: It is well accepted that the biological agents such as anti‐TNFα‐neutralizing antibodies (etanercept, infliximab, and adalimumab, etc.)and anti‐IL‐6‐neutralizing antibody (tocilizumab) target NF‐κB pathway to prevent joint destruction of RA patients.201